SCHEMBL3534232

SCHEMBL3534232

CC(C)(CN)C(N)c1nc(C=Cc2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)nc2cc(Cl)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.41
AKR1C3 P42330 1/20 0.39
LMNA P02545 3/20 0.38
KDM4E B2RXH2 2/20 0.38
KMT2A Q03164 4/20 0.37
POLB P06746 2/20 0.37
UBE2N P61088 1/20 0.37
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
TACR2 P21452 1/20 0.36
MEN1 O00255 2/20 0.36
ATM Q13315 1/20 0.36
HTT P42858 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MITF O75030 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
THRB P10828 1/20 0.35
HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534230 1.00 KCNA3 (0.41) KCNA3AKR1C3LMNAKDM4EKMT2A
SCHEMBL3535714 0.84 TUBB4A (0.40)
SCHEMBL3535717 0.84 TUBB4A (0.40)
SCHEMBL3540302 0.83 KCNA3 (0.38) KCNA3AKR1C3LMNAKDM4EKMT2A
SCHEMBL3540304 0.83 KCNA3 (0.38) KCNA3AKR1C3LMNAKDM4EKMT2A
SCHEMBL3537200 0.82 KCNA3 (0.39) KCNA3AKR1C3LMNAKDM4EKMT2A
SCHEMBL6666679 0.80 KCNA3 (0.37) KCNA3AKR1C3LMNAKDM4EKMT2A
SCHEMBL3537045 0.79 PDE5A (0.42) LMNAKDM4EKMT2AALDH1A1MEN1
SCHEMBL3537048 0.79 PDE5A (0.42) LMNAKDM4EKMT2AALDH1A1MEN1
SCHEMBL3536810 0.78 PDE5A (0.45) KCNA3KMT2AMEN1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7829566-B2 Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents MEDERSKI WERNER 2010-11-09 US disclosed
US-20070293667-A1 4-Amino-quinazolines MEDERSKI WERNER 2007-12-20 US disclosed
WO-2004030671-A2 USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
US-20040044204-A1 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-03-04 US disclosed
EP-1318985-A2 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024666-A2 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044204-A1 4-amino-quinazolines MRGPRX4, MRGPRX1, MRGPRX2 KCNA3 457/4885AKR1C3 3764/4885LMNA 2412/4885
US-20070293667-A1 4-Amino-quinazolines MRGPRX4, MRGPRX1, MRGPRX2 KCNA3 579/4885AKR1C3 3582/4885LMNA 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.